STAT3 and colitis: We next studied the contribution of STAT3 to DSS-colitis by pharmacological modulation using a small-molecule inhibitor of STAT3 identified by our group and being developed by Tvardi Therapeutic, Inc. TTI-101 targets the Src-homology (SH) 2 domain of STAT3 [26,36,37] and was shown to target STAT3 in mouse models of inflammation, fibrosis and cancer [26,27,28,29,30,31,32,33,34,35,36].